Rectal transmission of transmitted/founder HIV-1 is efficiently prevented by topical 1% tenofovir in BLT humanized mice.

by Morgan L Chateau, Paul W Denton, Michael D Swanson, Ian McGowan, J Victor Garcia
Published 2013-01-01

Exploring the feasibility of multi-site flow cytometric processing of gut associated lymphoid tissue with centralized data analysis for multi-site clinical trials.

by Ian McGowan, Peter A Anton, Julie Elliott, Ross D Cranston, Kathryn Duffill, Andrew D Althouse, Kevin L Hawkins, Stephen C De Rosa
Published 2015-01-01

Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel.

by Martin Cranage, Sally Sharpe, Carolina Herrera, Alethea Cope, Mike Dennis, Neil Berry, Claire Ham, Jonathan Heeney, Naser Rezk, Angela Kashuba, Peter Anton, Ian McGowan, Robin Shattock
Published 2008-08-01

Correlation between compartmental tenofovir concentrations and an ex vivo rectal biopsy model of tissue infectibility in the RMP-02/MTN-006 phase 1 study.

by Nicola Richardson-Harman, Craig W Hendrix, Namandjé N Bumpus, Christine Mauck, Ross D Cranston, Kuo Yang, Julie Elliott, Karen Tanner, Ian McGowan, Angela Kashuba, Peter A Anton
Published 2014-01-01

A multi-compartment single and multiple dose pharmacokinetic comparison of rectally applied tenofovir 1% gel and oral tenofovir disoproxil fumarate.

by Kuo-Hsiung Yang, Craig Hendrix, Namandje Bumpus, Julie Elliott, Karen Tanner, Christine Mauck, Ross Cranston, Ian McGowan, Nicola Richardson-Harman, Peter A Anton, Angela D M Kashuba
Published 2014-01-01

A phase 1 randomized, double blind, placebo controlled rectal safety and acceptability study of tenofovir 1% gel (MTN-007).

by Ian McGowan, Craig Hoesley, Ross D Cranston, Philip Andrew, Laura Janocko, James Y Dai, Alex Carballo-Dieguez, Ratiya Kunjara Na Ayudhya, Jeanna Piper, Florian Hladik, Ken Mayer
Published 2013-01-01

First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy.

by Peter A Anton, Terry Saunders, Julie Elliott, Elena Khanukhova, Robert Dennis, Amy Adler, Galen Cortina, Karen Tanner, John Boscardin, William G Cumberland, Ying Zhou, Ana Ventuneac, Alex Carballo-Diéguez, Lorna Rabe, Timothy McCormick, Henry Gabelnick, Christine Mauck, Ian McGowan
Published 2011-01-01

Project Gel a Randomized Rectal Microbicide Safety and Acceptability Study in Young Men and Transgender Women.

by Ian McGowan, Ross D Cranston, Kenneth H Mayer, Irma Febo, Kathryn Duffill, Aaron Siegel, Jarret C Engstrom, Alexyi Nikiforov, Seo-Young Park, Rhonda M Brand, Cindy Jacobson, Rebecca Giguere, Curtis Dolezal, Timothy Frasca, Cheng-Shiun Leu, Jill L Schwartz, Alex Carballo-Diéguez
Published 2016-01-01

Safety and Pharmacokinetics of a Tenofovir Alafenamide Fumarate-Emtricitabine based Oral Antiretroviral Regimen for Prevention of HIV Acquisition in Women: A Randomized Controlled...

by Andrea R. Thurman, MD, Jill L. Schwartz, MD, Mackenzie L. Cottrell, PharmD, Vivian Brache, Lic, Beatrice A. Chen, MD, MPH, Leila Cochón, Lic, Susan Ju, BA, Ian McGowan, MD PhD, James F. Rooney, MD, Scott McCallister, MD, Gustavo F. Doncel, MD PhD
Published 2021-06-01

Correction: Mucosal effects for tenofovir 1% gel

by Florian Hladik, Adam Burgener, Lamar Ballweber, Raphael Gottardo, Lucia Vojtech, Slim Fourati, James Y Dai, Mark J Cameron, Johanna Strobl, Sean M Hughes, Craig Hoesley, Philip Andrew, Sherri Johnson, Jeanna Piper, David R Friend, T Blake Ball, Ross D Cranston, Kenneth H Mayer, M Juliana McElrath, Ian McGowan
Published 2015-03-01

Mucosal effects of tenofovir 1% gel

by Florian Hladik, Adam Burgener, Lamar Ballweber, Raphael Gottardo, Lucia Vojtech, Slim Fourati, James Y Dai, Mark J Cameron, Johanna Strobl, Sean M Hughes, Craig Hoesley, Philip Andrew, Sherri Johnson, Jeanna Piper, David R Friend, T Blake Ball, Ross D Cranston, Kenneth H Mayer, M Juliana McElrath, Ian McGowan
Published 2015-02-01

A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study).

by Ian Mcgowan, Ross D Cranston, Kathryn Duffill, Aaron Siegel, Jarret C Engstrom, Alexyi Nikiforov, Cindy Jacobson, Khaja K Rehman, Julie Elliott, Elena Khanukhova, Kaleab Abebe, Christine Mauck, Hans M L Spiegel, Charlene S Dezzutti, Lisa C Rohan, Mark A Marzinke, Hiwot Hiruy, Craig W Hendrix, Nicola Richardson-Harman, Peter A Anton
Published 2015-01-01

High levels of adherence to a rectal microbicide gel and to oral Pre-Exposure Prophylaxis (PrEP) achieved in MTN-017 among men who have sex with men (MSM) and transgender women.

by Alex Carballo-Diéguez, Ivan C Balán, William Brown, Rebecca Giguere, Curtis Dolezal, Cheng-Shiun Leu, Mark A Marzinke, Craig W Hendrix, Jeanna M Piper, Barbra A Richardson, Cynthia Grossman, Sherri Johnson, Kailazarid Gomez, Stephanie Horn, Ratiya Pamela Kunjara Na Ayudhya, Karen Patterson, Cindy Jacobson, Linda-Gail Bekker, Suwat Chariyalertsak, Anupong Chitwarakorn, Pedro Gonzales, Timothy H Holtz, Albert Liu, Kenneth H Mayer, Carmen Zorrilla, Javier Lama, Ian McGowan, Ross D Cranston
Published 2017-01-01

Treatment with Commonly Used Antiretroviral Drugs Induces a Type I/III Interferon Signature in the Gut in the Absence of HIV Infection

by Sean M. Hughes, Claire N. Levy, Fernanda L. Calienes, Joanne D. Stekler, Urvashi Pandey, Lucia Vojtech, Alicia R. Berard, Kenzie Birse, Laura Noël-Romas, Brian Richardson, Jackelyn B. Golden, Michael Cartwright, Ann C. Collier, Claire E. Stevens, Marcel E. Curlin, Timothy H. Holtz, Nelly Mugo, Elizabeth Irungu, Elly Katabira, Timothy Muwonge, Javier R. Lama, Jared M. Baeten, Adam Burgener, Jairam R. Lingappa, M. Juliana McElrath, Romel Mackelprang, Ian McGowan, Ross D. Cranston, Mark J. Cameron, Florian Hladik
Published 2020-09-01